US biopharma Vertex Pharmaceuticals remains an evergreen pick in the stock market, announcing another set of financial results that exceeded expectations. 7 May 2024
A trial flop for Massachusetts, USA-based EyePoint Pharmaceuticals has triggered a sell-off from investors, with the price of a share dropping by around half. 7 May 2024
X4 Pharmaceuticals has secured US approval for Xolremdi (mavorixafor), for the treatment of WHIM syndrome (warts, hypogammaglobulinemia, infections and myelokat 30 April 2024
Swedish Orphan Biovitrum, a rare disease company also known as Sobi, is set to raise around 10 billion Swedish kroner ($920 million) in debt. 26 April 2024
Shares in Britain’s largest drugmaker, AstraZeneca, have surged to a multi-month high following better-than-expected financial results for the first quarter. 25 April 2024
A first-in-class treatment for paroxysmal nocturnal haemoglobinuria (PNH), Voydeya (danicopan), has been granted marketing authorization in Europe. 23 April 2024
A commercial stage biopharmaceutical R&D company, focused on the development of products that address the medical challenges in the therapeutic area of anti-infectives.